| Jun'18 | Jun'17 | |||||
|---|---|---|---|---|---|---|
Net sales to third parties | ||||||
0 | 0 | |||||
Other revenues | ||||||
0 | 0 | |||||
Cost of goods sold | ||||||
0 | 0 | |||||
Gross profit from continuing operations | ||||||
0 | 0 | |||||
Selling, General and Administration | ||||||
0 | 0 | |||||
Research and Development | ||||||
0 | 0 | |||||
Other income | ||||||
0 | 0 | |||||
Other expense | ||||||
0 | 0 | |||||
Operating income from continuing operations | ||||||
0 | 0 | |||||
Income from associated companies | ||||||
0 | 0 | |||||
Interest expense | ||||||
0 | 0 | |||||
Other financial income and expense | ||||||
0 | 0 | |||||
Income before taxes from continuing operations | ||||||
0 | 0 | |||||
Taxes | ||||||
0 | 0 | |||||
Net income | ||||||
0 | 0 | |||||
Attributable to | ||||||
Shareholders of Novartis AG | ||||||
0 | 0 | |||||
Non-controlling interests | ||||||
0 | 0 | |||||
Weighted average number of shares outstanding used in the basic earnings per share | ||||||
2,327 | 2,354 | |||||
Basic earnings per share [abstract] | ||||||
Total basic earnings per share | ||||||
3.34 | 0.84 | |||||
Adjusted weighted average number of ordinary shares outstanding | ||||||
2,346 | 2,373 | |||||
Diluted earnings per share [abstract] | ||||||
Total diluted earnings per share | ||||||
3.31 | 0.83 | |||||